Loss of exclusivityNovember 2028latest FDA-listed patent expiry
CompanyMEDRx →See this company's full patent-cliff portfolio
Drug detail
Brand name
BONDLIDO
Active ingredient
LIDOCAINE
Strength
10%
Dosage form
SYSTEM
Route
TOPICAL
Modality
Small molecule
FDA approval
September 2025
Marketing status
RX
Listed patents
Patent
Expires
Type
8722065
November 2028
product
Regulatory exclusivity
Code
Expires
NP
September 2028
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.